Researchers at UC San Diego School of Medicine have presented data that suggests a new HIV outbreak in Tijuana, Mexico, driven in part by “drug tourism” unabated by the closure of the international border due to the COVID-19 pandemic.
Join the UCLA Fielding School of Public for the 47th Lester Breslow Distinguished Lecture. Dr. Roger Detels — distinguished research professor of epidemiology at the UCLA Fielding School of Public Health and infectious diseases at the David Geffen School of Medicine at UCLA — will present opportunities realized that have contributed to advancing our understanding of disease pathogenesis as well as the shaping of public health policy and promoting of future public health leaders, both nationally and internationally. The event will be hosted by Dr. Ron Brookmeyer, dean of the UCLA Fielding School of Public Health.
Baltimore, Maryland, USA, February 8, 2021: The Global Virus Network (GVN), representing 68 Centers of Excellence and 10 Affiliates in 36 countries comprising foremost experts in every class of virus causing disease in humans, and the Centre for the AIDS Programme of Research in South Africa (CAPRISA) in Durban announced the addition of CAPRISA as GVN’s newest Center of Excellence.
Wistar Institute scientists take a promising step in the direction of developing an HIV vaccine that uses a unique native-like trimer to develop Tier-2 neutralizing antibodies—the kind that matter for combatting HIV—in mice for the first time.
Most teens and young adults know it’s possible to catch or spread a sexually transmitted infection by having unprotected oral sex, a new poll shows. But more than half underestimate the level of that risk, including many who focus on avoiding pregnancy risk, the data show.
A Case Western Reserve dental school researcher was awarded $3.7M in NIH grants to study the link between people living with HIV and higher rates of cancer and other diseases.
In it’s first year, the Fielding School’s UCLA Center for LGBTQ+ Advocacy, Research & Health (C-LARAH) has had impact across a spectrum of applied research and organizational work, focused on increasing equity for an underserved community.
About a fifth of young sexual minority males and transgender females are estimated to be engaging in transactional, or survival sex, according to results of a new survey study by Johns Hopkins Medicine researchers.
State laws in the US that require medical doctors (MDs) to determine which medications a nurse practitioner (NP) or physician assistant (PA) can prescribe, and under what conditions, may limit the number of patients who use HIV pre-exposure prophylaxis (PrEP), reports a study in The Journal of the Association of Nurses in AIDS Care (JANAC). The official journal of the Association of Nurses in AIDS Care, JANAC is published in the Lippincott portfolio by Wolters Kluwer.
While most people living with HIV have received at least one dose of the COVID-19 vaccine, younger and Black individuals are hesitant to get vaccinated and have lower vaccination rates, according to a new study by Rutgers researchers.
With this NIH grant, FAU researchers are developing an affordable, disposable self-testing HIV-1 chip that can selectively detect HIV from whole blood samples, be highly sensitive to detect HIV during the acute infection, treatment and viral rebound; be rapid within 40 minutes; highly stable without requiring refrigeration; and fully automated providing true sample-in-answer-out ability.
In a study using mice, a UCLA-led team of researchers have improved upon a method they developed in 2017 that was designed to kill HIV-infected cells. The advance could move scientists a step closer to being able to reduce the amount of virus, or even eliminate it, from infected people.
New UCLA-led research in mice suggests that adding a certain type of tomato concentrate to the diet can reduce the intestinal inflammation that is associated with HIV. Left untreated, intestinal inflammation can accelerate arterial disease, which in turn can lead to heart attack and stroke.
HIV replication in the human body requires that specific viral RNAs be packaged into progeny virus particles. A new study has found how a small difference in the RNA sequence can allow the viral RNA to be packaged for replication, creating potential targets for future HIV treatments.
Transgender men face significant health and social disparities, including barriers to health care, research, and essential HIV-related conversations with their health care providers. That is why Paige Wermuth, PhD, MPH, assistant professor in the Department of Management, Policy, and Community Health, and graduate student Lou Weaver of The University of Texas Health Science Center (UTHealth Houston) School of Public Health are launching a pilot project to examine and develop communication materials for trans men and their health care providers regarding HIV prevention.
While the rapid development of effective vaccines has helped combat the COVID-19 pandemic, key communities – especially people who are living with HIV – remain disproportionately impacted, and are at higher risk of severe disease and death. Finding an effective HIV vaccine is critically important, and to that end, the HIV Vaccine Trials Network (HVTN) is launching an expanded Faith Initiative that will help advance the work of finding a cure.
The National Institute of Allergy and Infectious Diseases awarded researchers at the Duke Human Vaccine Institute a contract that enables it to compete for projects advancing investigational vaccines to production for use in early clinical trials.
A highly anticipated clinical trial in eight sub-Saharan countries is the first to specifically evaluate the efficacy of a COVID-19 vaccine in people living with HIV, including those with poorly controlled infections. It also is the first study to evaluate the efficacy of vaccines – in this case, Moderna mRNA-1273 – against the omicron variant of SARS-CoV-2, the virus that causes COVID-19.
The University of Texas at El Paso will develop a sustainable public health intervention to suppress human immunodeficiency virus (HIV) in people who use drugs in the El Paso-Ciudad Juárez border region. The initiative will be funded by a $3 million grant from the National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA).
Racial bias among health care providers may limit the number of Black women who could be taking a daily pill to prevent HIV infection, according to a Rutgers-led study.
Among HIV-positive black and Latino men who have sex with men, the use of methamphetamine combined with intimate partner violence may increase the risk for developing chronic diseases such as cardiovascular disease and other disorders.
The first long-acting option to protect women from HIV, proven to reduce women’s HIV risk, has been recommended for use by the World Health Organization (WHO).
Dec. 1, 2021— People living with HIV experience more severe outcomes and have higher comorbidities from COVID-19 than people not living with HIV, according to the 2020 UNAIDS Global Update. In mid-2021, most people living with HIV did not have access to COVID-19 vaccines. This World AIDS Day, the Forum of International Respiratory Societies (FIRS), of which the American Thoracic Society is a founding member, is calling on governments, health advocates and non-government organisations to strengthen their response to AIDS and COVID-19 by making COVID-19 vaccines more accessible worldwide.
In a baseline scenario, the researchers project a rise in the ART-using population from about 670,000 in 2020 to nearly 910,000 by the end of 2030 if current trends in new HIV infections persist.
The Bronx is home to more than 27,000 people living with HIV, the majority of whom are Black or Hispanic men. People living with HIV have an increased risk for depression and substance use, which in turn can make adhering to daily antiviral treatments difficult, negatively impacting both quality of life and overall health.
Now, the National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine and Montefiore Health System two five-year grants totaling $7.6 million to study the structural and chemical changes in the brain of people living with HIV, depression, and cannabis use disorder.
Rutgers New Jersey Medical School’s Research with a Heart is recruiting participants for the MERCK– IMPOWER studies to assess an HIV prevention oral medication on sexual minority groups.
A new study published today reveals systematic biases among primary and HIV care providers about people who inject drugs and how those biases may impact access to pre-exposure prophylaxis (PrEP), a preventive, prescription-based medication that significantly reduces the risk of HIV infection through sexual behavior and injection practices.
Neuroimaging study reveals potential brain mechanism underlying chronic neuropathic pain in individuals with HIV. Findings may guide new clinical treatments targeting patients’ expectations for pain relief.
The new study provides valuable insights into the genetic variants associated with HIV-1C infection and AIDS progression in sub-Saharan Africa, potentially paving the way for new therapies.
The Rutgers School of Public Health and the Mason Gross School of the Arts have launched a collaboration to support community-engaged, arts-integrated research projects that will result in performances or productions of art.
Thanks to a new $16 million, five-year grant from the National Institute on Drug Abuse of the National Institutes of Health, Case Western Reserve University is launching a multi-institutional research effort dedicated to deepening understanding of the relationship between substance use and HIV.
The University at Albany has been awarded $1 million for the creation of a five-year, comprehensive program aimed at preventing HIV infections and substance use disorders among students.
A new trial by UC San Diego Health infectious disease specialist Maile Young Karris, MD, will use longitudinal questionnaires and qualitative interviews to assess the impact of living in an interconnected virtual village on the loneliness known to afflict older people with HIV.
Armed with a novel strategy they developed for bolstering the body’s immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections. Their findings were published today in the Journal of Clinical Investigation.
In recent years, crisis pregnancy centers (CPCs) have begun to offer some STI and HIV services, but new research from the University of Georgia suggests that these services may actually be hurting public health efforts to prevent and treat these infections.
Wistar is proud to announce Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH); Jane Shull, chief executive officer of Philadelphia FIGHT; philanthropist Ken Nimblett; Philadelphia Foundation and the Robert I. Jacobs Fund; and Philadelphia FIGHT will be honored at the Wistar Legacy Awards, a celebration of 25 years of continuous HIV research collaboration on Thursday, October 28 from 5:30 to 7:45 p.m.
A new $3.1-million, four-year grant co-led by faculty at Binghamton University, State University of New York could help African American and Latinx youth living with HIV.
A nationwide team of researchers, led by scientists at University of Utah Health and The Rockefeller University, has determined how a genetic mutation found in mice and monkeys interferes with viruses such as HIV and Ebola. They say the finding could eventually lead to the development of medical interventions in humans.
Researchers at the Uniformed Services University of the Health Sciences (USU) and Université de Montréal, Canada have discovered a way to potentially eliminate HIV-1 infection in infected individuals by using a new type of antibody-based therapeutics, according to a new study published Sept. 29 in mBio.
A family of proteins best known for their role in diminishing HIV infectivity may have the goods to outwit other emerging and re-emerging viruses, scientists have found.
The Association of Nurses in AIDS Care (ANAC) honors research led by Anne Teitelman, PhD, FNP-BC, FAANP, FAAN, Associate Professor Emerita in Penn Nursing’s Department of Family and Community Health, as the 2021 JANAC (Journal of the Association of Nurses in AIDS Care) Article of the Year.
A primary analysis of an experimental HIV vaccine regimen being studied in a high-incidence population of young women in sub-Saharan Africa found the experimental vaccine did not provide sufficient protection against HIV infection.
Researchers at Albert Einstein College of Medicine and the City University of New York Graduate School of Public Health and Health Policy (CUNYSPH) have been awarded a five-year, $14.5 million grant from the National Institutes of Health (NIH) to continue leading and expand their research on HIV treatment and care in five Central African nations.